KELIX bio to acquire PHI for $120m.

KELIX bio, an operator of a biopharmaceutical platform, agreed to acquire Pharmaceutical Institute, a pharmaceutical company established in Rabat, from $120m. “PHI is a high-quality pharmaceutical manufacturer that has built its reputation over three decades thanks to the values of the Sedrati family. The company has earned its unique position through an outstanding record of execution and a relentless focus on quality. We are privileged to have reached an agreement with the founders and look forward to welcoming them to KELIX bio,” Hocine Sidi-Said, KELIX bio CEO.